See more : Envirosuite Limited (EVS.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Syndax Pharmaceuticals, Inc. (SNDX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Syndax Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Menon Bearings Limited (MENONBE.BO) Income Statement Analysis – Financial Results
- The Joint Corp. (JYNT) Income Statement Analysis – Financial Results
- WWPKG Holdings Company Limited (8069.HK) Income Statement Analysis – Financial Results
- PT Alfa Energi Investama Tbk (FIRE.JK) Income Statement Analysis – Financial Results
- TTL Beteiligungs- und Grundbesitz-AG (TTO.DE) Income Statement Analysis – Financial Results
Syndax Pharmaceuticals, Inc. (SNDX)
About Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 139.71M | 1.52M | 1.52M | 1.52M | 2.11M | 1.22M | 627.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 12.00K | 454.00K | 456.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 51.00K |
| Gross Profit | -12.00K | -454.00K | 139.25M | 1.52M | 1.52M | 1.52M | 2.11M | 1.22M | 627.00K | 0.00 | 0.00 | 0.00 | -51.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 99.67% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 163.02M | 118.50M | 88.25M | 50.44M | 42.99M | 60.11M | 48.20M | 31.67M | 9.55M | 10.18M | 3.21M | 5.24M | 6.09M |
| General & Administrative | 0.00 | 33.26M | 25.24M | 22.51M | 16.06M | 17.29M | 15.86M | 13.32M | 11.59M | 11.16M | 5.36M | 3.49M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 66.92M | 33.26M | 25.24M | 22.51M | 16.06M | 17.29M | 15.86M | 13.32M | 11.59M | 11.16M | 5.36M | 3.49M | 3.49M |
| Other Expenses | 0.00 | 2.42M | -1.29M | -1.74M | 1.49M | 1.92M | 1.15M | -706.00K | -37.00K | 4.00K | -3.01M | -1.00K | 0.00 |
| Operating Expenses | 229.95M | 151.76M | 113.49M | 72.94M | 59.06M | 77.39M | 64.06M | 44.99M | 21.14M | 21.33M | 8.57M | 8.73M | 9.57M |
| Cost & Expenses | 229.95M | 151.76M | 113.49M | 72.94M | 59.06M | 77.39M | 64.06M | 44.99M | 21.14M | 21.33M | 8.57M | 8.73M | 9.62M |
| Interest Income | 21.16M | 5.87M | 403.00K | 841.00K | 1.57M | 0.00 | 0.00 | 0.00 | 161.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 208.00K | 3.14M | 1.90M | 2.36M | 1.57M | 1.94M | 1.42M | 956.00K | 1.58M | 0.00 | 0.00 | 0.00 | 1.99M |
| Depreciation & Amortization | 12.00K | 454.00K | 456.00K | 515.00K | 451.00K | 78.00K | 76.00K | 89.00K | 21.00K | 15.00K | 13.00K | 34.00K | 51.00K |
| EBITDA | -229.94M | -151.76M | 27.28M | -70.29M | -55.60M | -73.88M | -61.88M | -43.68M | -20.49M | -21.32M | -8.56M | -5.26M | -11.05M |
| EBITDA Ratio | 0.00% | 0.00% | 18.77% | -4,708.17% | -3,792.95% | -5,001.71% | -2,938.99% | -3,587.38% | -3,248.48% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -229.95M | -151.76M | 26.22M | -71.42M | -57.54M | -75.88M | -61.95M | -43.77M | -20.51M | -21.33M | -8.57M | -8.73M | -9.62M |
| Operating Income Ratio | 0.00% | 0.00% | 18.77% | -4,708.17% | -3,792.95% | -5,001.71% | -2,938.99% | -3,587.38% | -3,271.61% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 20.59M | 2.42M | -1.29M | -1.74M | 1.49M | 1.92M | 1.15M | -706.00K | -3.61M | 1.50M | -5.60M | -1.23M | -3.47M |
| Income Before Tax | -209.36M | -149.34M | 24.93M | -73.16M | -56.05M | -73.96M | -60.80M | -44.47M | -24.12M | -19.83M | -14.17M | -9.97M | -13.09M |
| Income Before Tax Ratio | 0.00% | 0.00% | 17.84% | -4,822.54% | -3,694.59% | -4,875.48% | -2,884.35% | -3,645.25% | -3,846.73% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -5.59M | -43.00K | -89.00K | -92.00K | 1.92M | -76.00K | -89.00K | 1.54M | -1.50M | 2.59M | 1.23M | 0.00 |
| Net Income | -209.36M | -143.75M | 24.93M | -73.07M | -55.96M | -73.96M | -60.80M | -44.47M | -24.12M | -19.83M | -14.17M | -9.97M | -13.09M |
| Net Income Ratio | 0.00% | 0.00% | 17.84% | -4,816.68% | -3,688.53% | -4,875.48% | -2,884.35% | -3,645.25% | -3,846.73% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.98 | -2.37 | 0.48 | -1.77 | -1.84 | -2.92 | -2.90 | -3.04 | -1.39 | -2.07 | -1.77 | -0.14 | -21.11 |
| EPS Diluted | -2.98 | -2.37 | 0.46 | -1.77 | -1.84 | -2.92 | -2.90 | -3.04 | -1.39 | -2.07 | -1.77 | -0.14 | -21.11 |
| Weighted Avg Shares Out | 70.26M | 60.76M | 52.06M | 41.31M | 30.49M | 25.37M | 21.00M | 14.62M | 17.37M | 9.60M | 8.01M | 70.28M | 619.96K |
| Weighted Avg Shares Out (Dil) | 70.37M | 60.76M | 53.62M | 41.31M | 30.49M | 25.37M | 21.00M | 14.62M | 17.37M | 9.60M | 8.01M | 70.28M | 619.96K |
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
WALTHAM, Mass. , Dec. 3, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on December 1, 2024 the Company granted inducement awards to purchase up to 23,900...
Syndax Announces Participation at the Citi 2024 Global Healthcare Conference
WALTHAM, Mass. , Nov. 27, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A.
US FDA approves Syndax's blood cancer drug
The U.S. Food and Drug Administration on Friday approved Syndax Pharmaceuticals' drug for the treatment of adult and pediatric patients with a type of blood cancer, sending the company's shares up 3% in after-hours trading.
Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation
– Approval based on positive data from the AUGMENT-101 clinical trial, in which Revuforj delivered robust and durable rates of remission in R/R acute leukemia patients with a KMT2A translocation – – Syndax to host conference call today at 6:00...
Syndax: Fall On NPM1m AML Data Of Revumenib Creates Buy Opportunity
Primary endpoint of pivotal phase 2 study met with statistical significance in using Revumenib for the treatment of relapsed/refractory mNPM1 AML patients; sNDA expected 1st half 2025. PDUFA action date of December 26th of 2024 deployed for FDA to decide...
Syndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of Revumenib
– Primary endpoint met with CR/CRh rate of 23% in pivotal Ph 2 cohort of R/R mNPM1 AML patients (p-value = 0.0014) – – 47% (30/64) ORR in a heavily pre-treated population, including 75% with prior venetoclax exposure in the...
Syndax Pharmaceuticals, Inc. (SNDX) Q3 2024 Earnings Call Transcript
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX ) Q3 2024 Earnings Conference Call November 5, 2024 4:30 PM ET Company Participants Sharon Klahre - Head, Investor Relations Michael Metzger - Chief Executive Officer Neil Gallagher - President & Head, R&D Steve Closter -...
Syndax Pharmaceuticals (SNDX) Reports Q3 Loss, Tops Revenue Estimates
Syndax Pharmaceuticals (SNDX) came out with a quarterly loss of $0.98 per share versus the Zacks Consensus Estimate of a loss of $1.13. This compares to loss of $0.73 per share a year ago.
Syndax Reports Third Quarter 2024 Financial Results and Provides Business Update
– New revumenib and Niktimvo ™ clinical data will be highlighted at 66th ASH Annual Meeting – – mNPM1 AML topline data from AUGMENT-101 expected in 4Q24; potential sNDA filing in 1H25 – – Revumenib NDA in R/R KMT2Ar acute leukemia is...
Syndax to Host ASH Investor Event in Person and via Webcast on December 9, 2024
WALTHAM, Mass. , Nov. 5, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that the Company will host an in-person investor event, along with a live webcast, on...
Source: https://incomestatements.info
Category: Stock Reports